Immix Biopharma (IMMX) Income towards Parent Company (2021 - 2026)
Immix Biopharma (IMMX) posted Income towards Parent Company of -$10.1 million for Q1 2026, down 317.98% sequentially from -$2.4 million in Q4 2025, and down 122.05% YoY from $45.7 million in Q1 2025.
Immix Biopharma (IMMX) Income towards Parent Company (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Income towards Parent Company for 6 years, with the latest figure at -$10.1 million in Q1 2026.
- Quarterly Income towards Parent Company fell 122.05% year-over-year to -$10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.7 million (down 3259.47% YoY) and the FY2025 annual result came in at -$21.2 million, down 1236.49% from the prior year.
- Income towards Parent Company slipped to -$10.1 million in Q1 2026 per IMMX's latest filing, from -$2.4 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $15.3 million in Q4 2024 and troughed at -$10.1 million in Q1 2026.
- A 5-year average of -$3.0 million and a median of -$3.6 million in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 649.04% in 2022, then jumped 1965.89% in 2024.
- Over 5 years, Income towards Parent Company stood at -$2.1 million in 2022, then surged by 60.06% to -$820134.0 in 2023, then surged by 1965.89% to $15.3 million in 2024, then slumped by 115.77% to -$2.4 million in 2025, then sank by 317.98% to -$10.1 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$10.1 million, -$2.4 million, and -$7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.56 Mn |
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -2.41 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | -7.15 Mn |
| Jun 30, 2024 | -4.41 Mn |
| Mar 31, 2024 | -5.33 Mn |
| Dec 31, 2023 | -820,134.00 |
| Sep 30, 2023 | -4.34 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -2.50 Mn |
| Dec 31, 2022 | -2.05 Mn |
| Sep 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.76 Mn |
| Sep 30, 2021 | -403,265.00 |